Overview

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of CAGM regimen in R/R DLBCL patients and to provide a safe and more effective approach for R/R DLBCL patients.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Treatments:
Azacitidine
Mitoxantrone
Obinutuzumab